Published 13 days ago

Eli Lilly’s Zepbound in shortage months after approval

Eli Lilly's weight loss drug Zepbound and diabetes drug Mounjaro will face shortages in most doses through the second quarter due to increased demand, per FDA's drug shortage database update.
Zepbound and Mounjaro, except for the 2.5-milligram versions, will experience scarcity, contradicting a prior announcement of limited availability until April.

Insights by Ground AI

Does this summary seem wrong?

0 Articles

All

Left

Center

Right

CNBC

Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says

The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.

15 days ago·United States

Read Full Article

The Hill

Eli Lilly’s Zepbound in shortage months after approval

The weight loss medication Zepbound has gone into shortage just months after it was approved by the Food and Drug Administration (FDA), with its manufacturer Eli Lilly blaming the situation on high demand. As of this week, most tirzepatide injections (sold commercially as Mounjaro and Zepbound) have limited availability, according to the FDA's shortage database. The cited reason for all the shortages of tirzepatide is "demand increase for the dr…

13 days ago·Washington, United States

Read Full Article

NBC News

As Zepbound shortage grows, Eli Lilly says no immediate end is in sight

Zepbound drugmaker Eli Lilly is working to increase its weight loss drug supply. But some steps to get there, including building a new plant, will take months to execute.

14 days ago·United States

Read Full Article

WTVB

Most doses of Lilly’s Mounjaro and Zepbound in limited availability, US FDA says

(Reuters) – The U.S. Food and Drug Administration website showed that most doses of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)

15 days ago

Read Full Article

NewsNation

Zepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly says

Almost all dosages of the drugs are listed as in shortage.

13 days ago·Chicago, United States

Read Full Article

WSAV

Zepbound shortage: Weight loss drugs' limited availability to continue, Eli Lilly says

(NEXSTAR) – New injectable drugs like Ozempic, Wegovy, Mounjaro and Zepbound have grown extremely popular with people seeking to lose weight. They're so in demand that most varieties are listed in short supply by the Food and Drug Administration – and that may be the case for the foreseeable future. Eli Lilly, the pharmaceutical company behind Zepbound and Mounjaro, told NBC News supply issues could last into 2025. "It is the demand that's caus…

13 days ago·Savannah, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left1Leaning Right0Center6Last Updated13 days agoBias Distribution

86% Center

Bias Distribution

86% of the sources are Center

86% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Eli Lilly’s Zepbound in shortage months after approval

0 Articles

0 Articles

Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says

Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says

Eli Lilly’s Zepbound in shortage months after approval

Eli Lilly’s Zepbound in shortage months after approval

As Zepbound shortage grows, Eli Lilly says no immediate end is in sight

As Zepbound shortage grows, Eli Lilly says no immediate end is in sight

Most doses of Lilly’s Mounjaro and Zepbound in limited availability, US FDA says

Most doses of Lilly’s Mounjaro and Zepbound in limited availability, US FDA says

Zepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly says

Zepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly says

Zepbound shortage: Weight loss drugs' limited availability to continue, Eli Lilly says

Zepbound shortage: Weight loss drugs' limited availability to continue, Eli Lilly says

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics